Additional cytogenetic changes and previous genotoxic exposure predict unfavorable prognosis in myelodysplastic syndromes and acute myeloid leukemia with der(1;7)(q10;p10)

Cancer Genetics and Cytogenetics

Volumn 165, Issue 2, 2006, Pages 161-166

  Hsiao, Hui Hua ^a,b   Sashida, Goro ^a   Ito, Yoshikazu ^a   Kodama, Atsushi ^a   Fukutake, Katsuyuki ^a   Ohyashiki, Junko H ^a   Ohyashiki, Kazuma ^a  

^a TOKYO MEDICAL UNIVERSITY   (Japan)

^b KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMETABOLITE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CHROMOSOME TRANSLOCATION 1; CHROMOSOME TRANSLOCATION 10; CHROMOSOME TRANSLOCATION 7; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOGENETICS; EXPOSURE; FEMALE; GENE FREQUENCY; GENETIC ANALYSIS; GENETIC RISK; GENOTOXICITY; HUMAN; MALE; MYELODYSPLASTIC SYNDROME; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RADIATION CARCINOGENESIS;

ACUTE DISEASE; AGED; AGED, 80 AND OVER; CHROMOSOME ABERRATIONS; CHROMOSOMES, HUMAN, PAIR 1; CHROMOSOMES, HUMAN, PAIR 7; FEMALE; HUMANS; LEUKEMIA, MYELOID; MALE; MIDDLE AGED; MUTAGENS; MYELODYSPLASTIC SYNDROMES; PROGNOSIS;

EID: 33644746245     PISSN: 01654608     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cancergencyto.2005.09.003     Document Type: Article

References (23)

1. J. Pedersen-Bjergaard, P. Philip, S.O. Larsen, G. Jensen, and K. Byrsting Chromosome aberrations and prognostic factors in therapy-related myelodysplasia and acute nonlymphocytic leukemia Blood 76 1990 1083 1091
2. C. Mecucci Molecular features of primary MDS with cytogenetic changes Leuk Res 22 1998 293 302
3. J. Pedersen-Bjergaard, S. Timshel, M.K. Andersen, A.S.T. Andersen, and P. Philip Cytogenetically unrelated clones in therapy-related myelodysplasia and acute myeloid leukemia: experience from the Copenhagen series updated to 180 consecutive cases Genes Chromosomes Cancer 23 1998 337 349
4. P. Mhawech, and A. Saleem Myelodysplastic syndrome: review of the cytogenetic and molecular data Crit Rev Oncol Hemat 40 2001 229 238
5. A.W. Block, A.J. Carroll, A. Hagemeijer, L. Micaux, K. van Lom, H.J. Olney, and M.R. Baer Rare recurring balanced chromosome abnormalities in therapy-related myelodysplastic syndromes and acute leukemia: report from an international workshop Genes Chromosomes Cancer 33 2002 401 412
6. M.M. LeBeau, R. Espinosa III, E.M. Davis, J.D. Eisenbart, R.A. Larson, and E.D. Green Cytogenetic and molecular delineation of a region of chromosome 7 commonly deleted in malignant myeloid diseases Blood 88 1996 1930 1935
7. N. Mauritzson, B. Johansson, L. Rylander, M. Albin, U. Stromberg, R. Billstrom, T. Ahlgren, Z. Mikoczy, F. Mitelman, and L. Hagmar The prognostic impact of karyotypic subgroups in myelodysplastic syndrome is strongly modified by sex Br J Haematol 113 2001 347 356
8. J.P.M. Geraedts, G.J. Ottolander, J.E. Den Polem, and O.G. Muntinghe An identical translocation between chromosome 1 and 7 in three patients with myelofibrosis and myeloid metaplasia Br J Haematol 44 1980 569 575
9. J.M.J.C. Scheres, T.W.J. Hustinx, R.S.G. Haldrinet, J.P.M. Geraedts, A. Hagemeijer, and M. van der Blyphilipsen Translocation 1;7 in dyshematopoiesis: possibly induced with a nonrandom geographic distribution Cancer Genet Cytogenet 12 1984 283 294
10. A.A. Sandberg, R. Morgan, B.K. Hecht, and F. Hecht Translocation (1;7)(p11;p11): a new myeloproliferative hematology entity Cancer Genet Cytogenet 18 1985 199 206
11. J.M.J.C. Scheres, T.W.J. Hustinx, J.P.M. Geraedts, H.W. Leeksma, and P.S. Meltzer Translocation 1;7 in hematologic disorders: a brief review of 22 cases Cancer Genet Cytogenet 18 1985 207 213
12. S. Horiike, M. Taniwaki, S. Misawa, H. Nishigaki, T. Okuda, S. Yokota, K. Kashima, J. Inazawa, and T. Abe The unbalanced 1;7 translocation in de novo myelodysplastic syndrome and its clinical implication Cancer 65 1990 1350 1354
13. B. Pedersen, J.M. Norgaard, B.B. Pedersen, N. Clausen, I.H. Rasmussen, and K. Thorling Many unbalanced translocations show duplication of a translocation participant. Clinical and cytogenetic implications in myeloid hematologic malignancies Am J Hematol 64 2000 161 169
14. J.D. Rowley, and H.J. Olney International workshop on the relationship for prior therapy to balanced chromosome aberrations in therapy-related myelodysplastic syndromes and acute leukemia: overview report Genes Chromosomes Cancer 33 2002 331 345
15. B. Pedersen Survival of patients with t(1;7)(p11;p11): report of two cases and review of the literature Cancer Genet Cytogenet 60 1992 53 59
16. P. Greenberg, C. Cox, M.M. LeBeau, P. Fenaux, P. Morel, G. Sanz, T. Vallespi, T. Hamblin, D. Oscier, K. Ohyashiki, K. Toyama, C. Aul, G. Mufti, and J. Bennett International scoring system for evaluating prognosis in myelodysplastic syndromes Blood 89 1997 2079 2088
17. H.H. Hsiao, Y. Ito, G. Sashida, J.H. Ohyashiki, and K. Ohyashiki De novo appearanceof der(1;7)(q10;p10) is associated with leukemic transformation and unfavorable prognosis in essential thrombocythemia Leuk Res 29 2005 1247 1252
18. J.W. Vardiman, N.L. Harris, and R.D. Brunning The World Health Organization (WHO) classification of the myeloid neoplasms Blood 100 2002 2292 2302
19. Mitelman F, Johansson B, Mertens F. Mitelman database of chromosome aberrations in cancer. http://www.cgap.nci.nih.gov/Chromosomes/ Mitelman. Accessed on August 15, 2005.
20. C. Mecucci, F. Ghione, G. Tricot, and H. Van den Berghe Combined trisomy 1q and monosomy 1q due to translocation 1;7 in myelodysplastic syndromes Cancer Genet Cytogenet 18 1985 193 197
21. L. Wang, S. Ogawa, A. Hangaishi, Y. Qiao, N. Hosoya, Y. Nanya, K. Ohyashiki, H. Mizoguchi, and H. Hirai Molecular characterization of the recurrent unbalanced translocation der(1;7)(q10;p10) Blood 102 2003 2597 2604
22. J. Pedersen-Bjergaard, and J.D. Rowley The balanced and the unbalanced chromosome aberrations of acute leukemia may develop in different ways and may contribute differently to malignant transformation Blood 83 1994 2780 2786
23. M.K. Andersen, and J. Pedersen-Bjergaard Increased frequency of dicentric chromosomes in therapy-related MDS and AML compared to de novo disease is significantly related to previous treatment with alkylating agents and suggests a specific susceptibility to chromosome breakage at the centromere Leukemia 14 2000 105 111